Affimed reveals 25% of staff were laid off in April in wake of phase 2 lymphoma fail

23 May 2023
www.fiercebiotech.com
Phase 2Phase 1Cell Therapy
Affimed reveals 25% of staff were laid off in April in wake of phase 2 lymphoma fail
Preview
Source: FierceBiotech
The “approximately” 25% reduction in full-time equivalent head count last month was the result of focusing Affimed's operations on three clinical programs.
April was a tricky month for Affimed. We already knew that a phase 2 fail prompted the end of plans to develop a bispecific antibody as a monotherapy in lymphoma. Now, Affimed has revealed that the resulting reorganization also meant a quarter of its employees were shown the exit.
The “approximately” 25% reduction in full-time equivalent head count last month was the result of focusing operations on Affimed's three remaining clinical programs, the company disclosed in a first-quarter earnings report this morning.
On that front, the company had better news to report today in the form of FDA clearance to begin a phase 2 study of AFM13 in combination with Artiva Biotherapeutics' AB-101 natural killer (NK) cells in patients with non-Hodgkin lymphoma. This suggests that there’s still a potential path for the bispecific antibody as a combo treatment, after it failed last month to demonstrate statistical significance in increasing survival when given as a monotherapy.
Data updates are also expected this year from three ongoing studies of the biotech’s bispecific EGFR/CD16A innate cell engager, dubbed AFM24, in various oncology indications including non-small cell lung cancer, colorectal cancer and advanced epidermal growth factor receptor-expressing solid tumorsadvanced epidermal growth factor receptor-expressing solid tumors.
The final third of Affimed’s clinical portfolio is AFM28, a tetravalent, bispecific CD123- and CD16A-binding innate cell engager that’s in a phase 1 trial as a monotherapy in patients with CD123-positive acute myeloid leukemiaCD123-positive acute myeloid leukemia. The company also plans to test the therapy in combination with NK cells.
To fund these operations, the Heidelberg, Germany-based biotech ended March with 155.8 million euros ($168 million) in cash and equivalents, which is expected to last into 2025.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.